Literature DB >> 7442804

Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A.

L D Leserman, J Barbet, F Kourilsky, J N Weinstein.   

Abstract

Many applications envisioned for liposomes in cell biology and chemotherapy require their direction to specific cellular targets. The ability to use antibody as a means of conferring specificity to liposomes would markedly increase their usefulness. We report here a method for covalently coupling soluble proteins, including monoclonal antibody and Staphylococcus aureus protein A (ref. 4), to small sonicated liposomes, by using the heterobifunctional cross-linking reagent N-hydroxysuccinimidyl 3-(2-pyridyldithio)propionate (SPDP, Pharmacia). Liposomes bearing covalently coupled mouse monoclonal antibody against human beta 2-microglobulin [antibody B1.1G6 (IgG2a, kappa) (B. Malissen et al., in preparation)] bound specifically to human, but not to mouse cells. Liposomes bearing protein A became bound to human cells previously incubated with the B1.1G6 antibody, but not to cells incubated without antibody. The coupling method results in efficient binding of protein to the liposomes without aggregation and without denaturation of the coupled ligand; at least 60% of liposomes bound functional protein. Further, liposomes did not leak encapsulated carboxyfluorescein (CF) as a consequence of the reaction.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7442804     DOI: 10.1038/288602a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  44 in total

Review 1.  Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.

Authors:  Nazila Kamaly; Zeyu Xiao; Pedro M Valencia; Aleksandar F Radovic-Moreno; Omid C Farokhzad
Journal:  Chem Soc Rev       Date:  2012-03-05       Impact factor: 54.564

2.  Selective modulation with liposomes containing Der. P1 labelled with monoclonal antibodies.

Authors:  G P Rombi; G Piu
Journal:  Cytotechnology       Date:  1991-02       Impact factor: 2.058

Review 3.  Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release.

Authors:  Nazila Kamaly; Basit Yameen; Jun Wu; Omid C Farokhzad
Journal:  Chem Rev       Date:  2016-02-08       Impact factor: 60.622

4.  Design of liposome to improve encapsulation efficiency of gelonin and its effect on immunoreactivity and ribosome inactivating property.

Authors:  A Alam; S R Bhuri; A K Mavila; V Singh
Journal:  Mol Cell Biochem       Date:  1992-06-26       Impact factor: 3.396

5.  Improvement of amphotericin B activity during experimental cryptococcosis by incorporation into specific immunoliposomes.

Authors:  F Dromer; J Barbet; J Bolard; J Charreire; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 6.  Nanocarriers for tracking and treating diseases.

Authors:  Sean Marrache; Rakesh Kumar Pathak; Kasey L Darley; Joshua H Choi; Dhillon Zaver; Nagesh Kolishetti; Shanta Dhar
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

7.  Antibody-targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication.

Authors:  J P Leonetti; P Machy; G Degols; B Lebleu; L Leserman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

8.  Acid-labile mPEG-vinyl ether-1,2-dioleylglycerol lipids with tunable pH sensitivity: synthesis and structural effects on hydrolysis rates, DOPE liposome release performance, and pharmacokinetics.

Authors:  Junhwa Shin; Pochi Shum; Jessica Grey; Shin-ichi Fujiwara; Guarov S Malhotra; Andres González-Bonet; Seok-Hee Hyun; Elaine Moase; Theresa M Allen; David H Thompson
Journal:  Mol Pharm       Date:  2012-10-03       Impact factor: 4.939

9.  Efficient transfection of human interferon-beta gene to human glioma cells by means of cationic multilamellar liposomes coupled with a monoclonal antibody [corrected].

Authors:  J Yoshida; M Mizuno; K Yagi
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

10.  Cross linking of anti-B16 melanoma monoclonal antibodies to lymphokine activated killer (LAK) cells: possible role in the therapy of B16 melanoma.

Authors:  A Eisenthal; S A Rosenberg
Journal:  Clin Exp Metastasis       Date:  1988 Sep-Oct       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.